Neurofibromatoses Type II - Pipeline Review Market Size, Share & Research Report 2015 Radiant Insights, Inc
Summary Radiant Insights's, 'Neurofibromatoses Type II - Pipeline Review, H2 2015', provides an overview of the Neurofibromatoses Type II's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects. Read Complete Report with TOC @ http://www.radiantinsights.com/research/neurofibromatoses-type-ii-pipeline-review-h2-2015 Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Summary
Radiant Insights's, 'Neurofibromatoses Type II - Pipeline Review, H2 2015', provides an overview of the Neurofibromatoses Type II's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/neurofibromatoses-type-ii-pipeline-review-h2-2015
Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - <strong>Pipeline</strong> <strong>Review</strong> <strong>Market</strong> <strong>Size</strong>, <strong>Share</strong><br />
& <strong>Research</strong> <strong>Report</strong> <strong>2015</strong> <strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Summary<br />
<strong>Radiant</strong> <strong>Insights</strong>'s, '<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - <strong>Pipeline</strong> <strong>Review</strong>, H2 <strong>2015</strong>', provides an overview of<br />
the <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong>'s therapeutic pipeline.<br />
This report provides comprehensive information on the therapeutic development for<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong>, complete with comparative analysis at various stages, therapeutics<br />
assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule<br />
type, along with latest updates, and featured news and press releases. It also reviews key players<br />
involved in the therapeutic development for <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> and special features on latestage<br />
and discontinued projects.<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/neurofibromatoses-type-ii-pipeline-review-h2-<strong>2015</strong><br />
<strong>Radiant</strong> <strong>Insights</strong>'s report features investigational drugs from across globe covering over 20 therapy<br />
areas and nearly 3,000 indications. The report is built using data and information sourced from<br />
<strong>Radiant</strong> <strong>Insights</strong>'s proprietary databases, Company/University websites, SEC filings, investor<br />
presentations and featured press releases from company/university sites and industry-specific third<br />
party sources, put together by <strong>Radiant</strong> <strong>Insights</strong>'s team. Drug profiles/records featured in the report<br />
undergoes periodic updation following a stringent set of processes that ensures that all the profiles are<br />
updated with the latest set of information. Additionally, processes including live news & deals<br />
tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent<br />
developments are captured on a real time basis.<br />
The report enhances decision making capabilities and help to create effective counter strategies to<br />
gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to<br />
produce first-in-class and best-in-class products.<br />
Scope<br />
- The report provides a snapshot of the global therapeutic landscape of <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong><br />
- The report reviews key pipeline products under drug profile section which includes, product<br />
description, MoA and R&D brief, licensing and collaboration details & other developmental activities<br />
- The report reviews key players involved in the therapeutics development for <strong>Neurofibromatoses</strong><br />
<strong>Type</strong> <strong>II</strong> and enlists all their major and minor projects<br />
- The report summarizes all the dormant and discontinued pipeline projects<br />
- A review of the <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> products under development by companies and<br />
universities/research institutes based on information derived from company and industry-specific<br />
sources
- <strong>Pipeline</strong> products coverage based on various stages of development ranging from pre-registration till<br />
discovery and undisclosed stages<br />
- A detailed assessment of monotherapy and combination therapy pipeline projects<br />
- Coverage of the <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> pipeline on the basis of target, MoA, route of<br />
administration and molecule type<br />
- Latest news and deals relating related to pipeline products<br />
Reasons To Buy<br />
- Provides strategically significant competitor information, analysis, and insights to formulate<br />
effective R&D development strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies<br />
to gain competitive advantage<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/neurofibromatoses-type-ii-pipeline-review-h2-<strong>2015</strong><br />
- Identify and understand important and diverse types of therapeutics under development for<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong><br />
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline<br />
- Devise corrective measures for pipeline projects by understanding <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong><br />
pipeline depth and focus of Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with<br />
the most attractive projects to enhance and expand business potential and scope<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors<br />
that drove them from pipeline<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 4<br />
List of Figures 4<br />
Introduction 5<br />
<strong>Radiant</strong> <strong>Insights</strong> <strong>Report</strong> Coverage 5
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> Overview 6<br />
Therapeutics Development 7<br />
<strong>Pipeline</strong> Products for <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Overview 7<br />
<strong>Pipeline</strong> Products for <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Comparative Analysis 8<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Therapeutics under Development by Companies 9<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Therapeutics under Investigation by Universities/Institutes 10<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - <strong>Pipeline</strong> Products Glance 11<br />
Clinical Stage Products 11<br />
Early Stage Products 12<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Products under Development by Companies 13<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Products under Investigation by Universities/Institutes 14<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Companies Involved in Therapeutics Development 15<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/neurofibromatoses-type-ii-pipeline-review-h2-<strong>2015</strong><br />
Arno Therapeutics, <strong>Inc</strong>. 15<br />
CalAsia Pharmaceuticals, <strong>Inc</strong>. 16<br />
Lixte Biotechnology Holdings, <strong>Inc</strong>. 17<br />
Nexgenix Pharmaceuticals, LLC 18<br />
Novartis AG 19<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Therapeutics Assessment 20<br />
Assessment by Monotherapy Products 20<br />
Assessment by Target 21<br />
Assessment by Mechanism of Action 23<br />
Assessment by Route of Administration 25<br />
Assessment by Molecule <strong>Type</strong> 27<br />
Drug Profiles 28<br />
AR-42 - Drug Profile 28<br />
Product Description 28
Mechanism of Action 28<br />
R&D Progress 28<br />
everolimus - Drug Profile 30<br />
Product Description 30<br />
Mechanism of Action 30<br />
R&D Progress 30<br />
FRAX-597 - Drug Profile 36<br />
Product Description 36<br />
Mechanism of Action 36<br />
R&D Progress 36<br />
LB-201 - Drug Profile 37<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/neurofibromatoses-type-ii-pipeline-review-h2-<strong>2015</strong><br />
Product Description 37<br />
Mechanism of Action 37<br />
R&D Progress 37<br />
LB-205 - Drug Profile 38<br />
Product Description 38<br />
Mechanism of Action 38<br />
R&D Progress 38<br />
NXD-30001 - Drug Profile 39<br />
Product Description 39<br />
Mechanism of Action 39<br />
R&D Progress 39<br />
Small Molecules to Inhibit Hsp90 for Neurofibromatosis <strong>Type</strong> 2 - Drug Profile 41<br />
Product Description 41<br />
Mechanism of Action 41<br />
R&D Progress 41
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Recent <strong>Pipeline</strong> Updates 42<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Dormant Projects 48<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Product Development Milestones 49<br />
Featured News & Press Releases 49<br />
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42 49<br />
Appendix 50<br />
Methodology 50<br />
Coverage 50<br />
Secondary <strong>Research</strong> 50<br />
Primary <strong>Research</strong> 50<br />
Expert Panel Validation 50<br />
Contact Us 50<br />
Disclaimer 51<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/neurofibromatoses-type-ii-pipeline-review-h2-<strong>2015</strong><br />
List of Tables<br />
Number of Products under Development for <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong>, H2 <strong>2015</strong> 7<br />
Number of Products under Development for <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Comparative Analysis, H2<br />
<strong>2015</strong> 8<br />
Number of Products under Development by Companies, H2 <strong>2015</strong> 9<br />
Number of Products under Investigation by Universities/Institutes, H2 <strong>2015</strong> 10<br />
Comparative Analysis by Clinical Stage Development, H2 <strong>2015</strong> 11<br />
Comparative Analysis by Early Stage Development, H2 <strong>2015</strong> 12<br />
Products under Development by Companies, H2 <strong>2015</strong> 13<br />
Products under Investigation by Universities/Institutes, H2 <strong>2015</strong> 14<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - <strong>Pipeline</strong> by Arno Therapeutics, <strong>Inc</strong>., H2 <strong>2015</strong> 15<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - <strong>Pipeline</strong> by CalAsia Pharmaceuticals, <strong>Inc</strong>., H2 <strong>2015</strong> 16<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - <strong>Pipeline</strong> by Lixte Biotechnology Holdings, <strong>Inc</strong>., H2 <strong>2015</strong> 17<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - <strong>Pipeline</strong> by Nexgenix Pharmaceuticals, LLC, H2 <strong>2015</strong> 18
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - <strong>Pipeline</strong> by Novartis AG, H2 <strong>2015</strong> 19<br />
Assessment by Monotherapy Products, H2 <strong>2015</strong> 20<br />
Number of Products by Stage and Target, H2 <strong>2015</strong> 22<br />
Number of Products by Stage and Mechanism of Action, H2 <strong>2015</strong> 24<br />
Number of Products by Stage and Route of Administration, H2 <strong>2015</strong> 26<br />
Number of Products by Stage and Molecule <strong>Type</strong>, H2 <strong>2015</strong> 27<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> Therapeutics - Recent <strong>Pipeline</strong> Updates, H2 <strong>2015</strong> 42<br />
<strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Dormant Projects, H2 <strong>2015</strong> 48<br />
List of Figures<br />
Number of Products under Development for <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong>, H2 <strong>2015</strong> 7<br />
Number of Products under Development for <strong>Neurofibromatoses</strong> <strong>Type</strong> <strong>II</strong> - Comparative Analysis, H2<br />
<strong>2015</strong> 8<br />
Read Complete <strong>Report</strong> with TOC @<br />
http://www.radiantinsights.com/research/neurofibromatoses-type-ii-pipeline-review-h2-<strong>2015</strong><br />
About <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market<br />
research reports, helping them in the decision making process. We have a comprehensive collection of<br />
reports, covering over 40 key industries and a host of micro markets. In addition to over extensive<br />
database of reports, our experienced research coordinators also offer a host of ancillary services such<br />
as, research partnerships/ tie-ups and customized research solutions.<br />
For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong><br />
Contact:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Blog URL: http://www.radiantinsightsinc.blogspot.com
Change language